Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01561690 | A Study of ARRY-502 in Patients With Persistent Asthma | PHASE2 | COMPLETED | 184 | — | — | Apr 2, 2012 | Jun 10, 2013 | Oct 30, 2023 | 43 | United States |
| Arm | Type | Description |
|---|---|---|
| ARRY-502 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARRY-502, CRTh2 antagonist; oral | DRUG | multiple dose, single schedule |
| Placebo; oral | DRUG | matching placebo |
Key Inclusion Criteria: * Documented history of bronchial asthma diagnosed at least 6 months prior to study start and prior to the age of 40 years. * Body mass index (BMI) of 18 to 35 inclusive. * An ACQ score of ≥ 1.5 at specified time points prior to first dose of study drug. * A best prebronchod...